Clinical Trial: A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07813039) titled 'A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation' on Sept. 04.

Brief Summary: The purpose of this study is to evaluate the relative bioavailability of VX-581 tablet formulation compared to a suspension formulation along with its safety and tolerability.

Study Start Date: Sept. 07

Study Type: INTERVENTIONAL

Condition: Cystic Fibrosis

Intervention: DRUG: VX-581

Tablet and Suspension for Oral Administration.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Vertex Pharmaceuticals Incorporated

Published by HT Digital Content Services with permission from Health Daily Digest....